11th Annual Drug Discovery Leaders Summit
Open Innovation Symposium 8th June, Drug Discovery Leaders Summit 9th & 10th June
Wednesday 9th June 2010 to Thursday 10th June 2010
Fairmont le Montreux Palace, Montreux, Switzerland, -
£0.00/person
Over 2 days, the comprehensive and scientific conference programme will feature key note addresses, case study presentations, panel and roundtable discussions of over 45 senior level industry speakers from leading pharmaceutical, biotechnology organisations as well as academia covering the following hot topics:
R&D STRATEGIES & BUSINESS MODELS AND PHARMA/BIOTECH ALLIANCES COLLABORATIONS–Challenges and strategies to enhance productivity in drug discovery such as open innovation, innovative business models, lean thinking and the benefits of industry and academic alliances
MEDICINAL CHEMISTRY / DRUG DESIGN –Reducing attrition in development, fragment based techniques, flow chemistry, reducing risk of toxicity, structure based discovery as well as hit identification strategies
SCREENING TECHNIQUES & ASSAY DEVELOPMENT – Improving quality of assays, compound selection, target selection and validation, as well as cost effective lead identification Initiatives for HTS, HCS and label free as well as the potential of pluripotent stem cells
BIOMARKERS & PERSONALISED / TRANSLATIONAL MEDICINE –Translational medicine and diagnostic case studies as well as how Biomarkers facilitate early decision making in early development
BIOINFORMATICS –Systems biology, computational modelling, ADMET & PK/ PD modelling as well as knowledge management and data intergration tools in Drug Safety
BIOLOGICS – Strategies to integrate biologics into an organisation, including presentations in phage display in peptides, a panel discussion on biobetters, case study on pepducins
|
 |
|
|
| Hear insights and views from our leading line up of industry experts: |
|
|
|
Claude Bertrand, Executive Vice President & Chief Scientific Officer, Ipsen
|
|
|
|
Andrew von Eschenbach, Senior Advisor, Greenleaf Health
|
|
|
|
John Overington, Team Leader, Chemogenomics, EMBL - Europeane Bioinformatics Institute
|
|
|
|
John Desjarlais, Vice President, Research, Xencor
|
|
|
|
Steve Hunt lll, Senior Vice President, Discovery Research, Anchor Therapeutics
|
|
|
|
Salvatore Alesci, Senior Director & Head, Translational Immunology Pfizer
|
|
|
|
Stephen Friend, President, CEO and Co-Founder, Sage Bionetworks
|
|
|
|
Harren Jhoti, CEO, Astex Therapeutics
|
|
|
|
Jay P. Siegel, Chief Biotechnology Officer, Johnson & Johnson
|
|
|
|
Marc Pfister, Executive Director, Discovery Medicine, and Clinical Pharmacology, head of Strategic Modeling and Simulation, Bristol Myers Squibb
|
|
|
|
Steven Ley, BP 1702 Professor of Organic Chemistry, Innovative technology Centre, Department of Chemistry, University of Cambridge
|
|
|
|
Jeremy Everett, Vice President, Special Operations, Worldwide Research Centres of Emphasis, Pfizer
|
|
|
|
Ian Tomlinson, Senior Vice President, Biopharmaceuticals R&D, GlaxoSmithKline
|
|
|
|
Gurmil Gendeh, Market Development Manager - Biopharmaceuticals, Dionex
|
|
|
|
Reto Stocklin, President and CEO, Atheris Laboratories, Switzerland
|
|
|
|
Marjoleen Nijsen, Head pre-clinical PH/PD Abbott
|
|
|
|
Per Kallblad CEO, Beactica AB
|
|
|
|
Christian Zahnd, CEO, Molecular Partners
|
|
|
|
Michel Pairet, Corporate Senior Vice President, Boehringer-Ingelheim
|
|
|
|
Andreas Sewing, Research Fellow, Director, Primary Pharmacology Unit, Pfizer
|
|
|
|
Andy Davis, Associate Director, Physical & Metabolic Sciences, AstraZeneca
|
|
|
|
Jens R. Sydor, Head DMPK Ludwigshafen, Abbott
|
|
|
|
Mark Bunnage, Executive Director, Medicinal Chemistry, Pfizer
|
|
|
|
Jutta Heim, Chief Technology Officer, Evolva S.A
|
|
|
|
Søren Bregenholt, COO, Symphogen
|
|
|
|
Maria Miteva, Senior Scientist, <Molecules Therapeutiques In Silico (Mti) Universite Paris
|
|
|
|
Andrea Cavalli, Senior Scientist, Computational Chemistry, Department of Drug Discovery and Development, Italian Institute of Technology
|
|
|
|
Troels Koch, Vice Preseident & CTO, Santaris Pharma A/S
|
|
|
|
Craig Johnstone, Value Chain Leader, RA-CVGI, AstraZeneca
|
|
|
|
Orest Hurko, Assistant Vice President Discovery Translational Research, Pfizer
|
|
|
|
Iain Brogan, Senior Director, Head non-clinical Development, OSI Prosidion
|
|
|
|
Jeffrey Waring, Associate Research Fellow, Senior Group Leader, Neuroscience Biomarker Abbott
|
|
|
|
David J. Heard, Group Head Bioinformatics in Investigative Toxicology, Preclinical Safety, Novartis Institutes for Biomedical Research
|
|
|
|
Jürgen Moll, Director, Dep. Cell Biology, Oncology, Nerviano Medical Sciences
|
|
|
|
Jin Li, Director of Director of Global Compound Sciences, DECS Lead Generation AstraZeneca
|
|
|
|
Paul Wyatt, Director of Drug Discovery, Division of Biological Chemistry & Drug Discovery, College, University of Dundee
|
|
|
|
Birgit Schoeberl, Vice President of Discovery, Merrimack Pharmaceuticals
|
|
|
|
Nick Terrett, Chief Scientific Officer, Ensemble Discovery Corporation
|
|
|
|
Rob Hayes, CSO, Centyrex a J&J Internal Venture
|
|
|
|
Anthony Davies, HCA Research Facility Manager, Trinity College Dublin
|
|
|
|
|
|
|
|
|
Programme
